Skip Ribbon Commands
Skip to main content
Menu
Dr Tan Wan Ling from National Cancer Centre Singapore

Dr Tan Wan Ling

MBBS, MRCK (UK), M Med (Internal Med) 

Consultant

Specialty: Medical Oncology

Sub-specialties: Head & Neck, Thoracic-Oncology, Uro-Oncology

Conditions Treated by this Doctor:
Head and Neck Cancer, Thoracic Cancers, Uro-Oncology.

Clinical Appointments

  • Associate Consultant SingHealth Duke-NUS Lung Centre
  • Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Adjunct Instructor

Profile

Dr Tan Wan Ling is currently an Consultant with the Thoracic/Head & Neck/ Uro-oncology team in the department of Medical Oncology at the National Cancer Centre Singapore, with a keen interest in thoracic and head & neck oncology. She hopes to pursue research goals in these fields and to contribute in the nurturing and education of junior doctors.

Education

  • MBBS 
  • MRCK (UK)
  • M. Med (Internal Med)

Professional Appointments and Committee Memberships

  • Consultant, Department of Medical Oncology, National Cancer Centre Singapore 
  • Singapore Medical Association, Member 
  • Singapore Society of Oncology (SSO), Member 
  • European Society for Medical Oncology (ESMO), Member

Awards

  • Outstanding Resident Award (Singhealth Residency) 2014
  • The Singhealth Best Medical Officer Award (2013) 
  • The Singhealth Best Medical Officer Award (2012)

Research Interests

  • Thoracic and head & neck oncology

Publications and Research Trials

  • Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Chowbay B. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. J Thorac Oncol. 2016 Nov 28. pii: S1556-0864(16)33533-X. doi: 10.1016/j.jtho.2016.11.2225. [Epub ahead of print] 
  • Choo SP, Tan WL, Brian Goh, David Tai, Andrew Zhu. Comparison of Hepatocellular Carcinoma in Eastern versus Western Populations. Cancer. 2016 Sep 13. doi: 10.1002/cncr.30237. [Epub ahead of print] 
  • Tan WL, Tan EH, Lim DW, Ng QS, Tan DS, Jain A, Ang MK. Advances in systemic treatment for nasopharyngeal carcinoma. Chin Clin Oncol. 2016 Apr;5(2):21. doi: 10.21037/cco.2016.03.03. 
  • Tan WL, Ng QS. The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung. Transl Lung Cancer Res. 2016 Feb;5(1):106-9. doi: 10.3978/j.issn.2218-6751.2015.10.12. 

Research Trials